T-Neuro Pharma Welcomes Renowned Alzheimer’s Researcher Dr. Jeffrey Cummings as Chair of Scientific Advisory Board
T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative therapies for neurodegenerative diseases, announced today the appointment of Dr. Jeffrey Cummings, MD, ScD as Chair of its Scientific Advisory Board (SAB). Dr. Cummings, a world-renowned expert in Alzheimer’s disease research and clinical trials, brings…
T-Neuro Pharma Announces Publication of Groundbreaking Alzheimer’s Research in Prestigious Journal
ALBUQUERQUE, New Mexico — T-Neuro Pharma, a leading biotechnology company dedicated to developing innovative diagnostics and therapeutics for neurodegenerative diseases, announced the publication of a landmark research article in Proceedings of the National Academy of Sciences(PNAS), a peer-reviewed journal of the National Academy of Sciences….
CEO Making Strides in the Diagnosis of Alzheimer’s Disease Named One of the Three Fellows for LANL’S Prestigious “LEEP” Program
Albuquerque, NM – Los Alamos National Laboratory recently launched the New Mexico Lab-Embedded Entrepreneur Program (New Mexico LEEP) in January of 2022. Through this program, entrepreneurs are provided a two-year fellowship that focuses on technical solutions to society’s largest concerns. These solutions, also referred to as…
T-Neuro Pharma takes a new approach to Alzheimer’s Disease diagnosis and treatment
ALBUQUERQUE — While the vast majority of Alzheimer’s Disease (AD) clinical trials have focused on decreasing beta-amyloid (the sticky protein fragment that gums up the brain and kills its cells) 99.6% of these trials have failed. The 0.4% that succeeded only treat symptoms, but do…